title: Wogonin inhibits osteoclast formation induced by lipopolysaccharide.
abstract: To evaluate the inhibitory activity of wogonin against lipopolysaccharide (LPS)-induced bone resorption, we investigated the effect of wogonin on osteoclastogenesis induced by LPS. Wogonin inhibited LPS-induced osteoclastogenesis in co-cultures of mouse calvaria-derived osteoblasts and bone marrow-derived pre-osteoclasts. Wogonin also suppressed osteoclastogenesis in LPS-injected mouse calvaria. In osteoblasts, the upregulation of receptor activator of nuclear factor-kappaB (RANKL) expression and the downregulation of osteoprotegerin (OPG) expression by LPS were inhibited by wogonin. Wogonin and NS-398, a COX-2 inhibitor, suppressed LPS-stimulated PGE(2) production in osteoblasts. NS-398 inhibited the effect of LPS on RANKL and OPG expression in osteoblasts. These results suggest that wogonin acts as an inhibitor of LPS-induced osteoclastogenesis through downregulation of RANKL and upregulation of OPG expression via blockage of PGE(2) production. Based on these results, wogonin has potential for use as a therapeutic agent in bacteria-induced bone resorption.
authors.affiliation: Department of Oral Biology, BK21 Project, Oral Science Research Center, and Research Center for Orofacial Hard Tissue Regeneration, Yonsei University College of Dentistry, Seoul, Korea.
authors.forename: Sungil
authors.initials: S
authors.lastname: Jang
authors.forename: Eun Jung
authors.initials: EJ
authors.lastname: Bak
authors.forename: Minyoung
authors.initials: M
authors.lastname: Kim
authors.forename: Jin Moon
authors.initials: JM
authors.lastname: Kim
authors.forename: Won-Yoon
authors.initials: WY
authors.lastname: Chung
authors.forename: Jeong-Heon
authors.initials: JH
authors.lastname: Cha
authors.forename: Yun-Jung
authors.initials: YJ
authors.lastname: Yoo
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000378:metabolism; D002454:Cell Differentiation; D002478:Cells, Cultured; D018920:Coculture Techniques; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000096:biosynthesis; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D044950:Flavanones / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009578:Nitrobenzenes / Q000494:pharmacology; D010010:Osteoclasts / Q000187:drug effects*; D053244:Osteoprotegerin / Q000378:metabolism; D053245:RANK Ligand / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D016861:Cyclooxygenase Inhibitors; D004365:Drugs, Chinese Herbal; D044950:Flavanones; D008070:Lipopolysaccharides; D009578:Nitrobenzenes; D053244:Osteoprotegerin; D053245:RANK Ligand; D013449:Sulfonamides; C505689:Tnfsf11 protein, mouse; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D015232:Dinoprostone; C085514:wogonin